Livagen
Aliases: Lys-Glu-Asp-Ala · KEDA
Last verified: 2026-09-23
The short version
A hepatoprotective tetrapeptide — liver regeneration and immunomodulation; studied in the elderly for liver and GI function. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + small Russian clinical series. Status: research chemical. Not approved in the West.
Identity & type
- Molecular type
- bioregulator
- Origin
- A hepatoprotective tetrapeptide — liver regeneration and immunomodulation; studied in the elderly for liver and GI function.
Mechanism of action
Gene-regulatory action on hepatocytes; antioxidant and antifibrotic properties.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Livagen. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–5 mg/day SC in courses. A liver bioregulator: improved digestive tone and a "lighter" liver reported in courses; all anecdotal/Russian data.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A liver bioregulator: improved digestive tone and a "lighter" liver reported in courses; all anecdotal/Russian data.
Protocol — official vs community
Official / label
No approved protocol exists. Livagen is a research peptide bioregulator (Lys-Glu-Asp-Ala) with no registered drug product in any major market.
Duration: —
Preclinical hepatoprotection plus small Russian clinical series; no Western regulatory review.
Community (anecdotal)
1–5 mg SC daily for 10–20 days.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
The regimen is the shared Khavinson course pattern; only the liver/hepatoprotection targeting claim distinguishes it from the rest of the series.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + small Russian clinical series.
Preclinical evidence
Preclinical + small Russian clinical series.
Known risks
- None reported.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.